PROCEPT BioRobotics (PRCT) TD Cowen 46th Annual Health Care Conference summary
Event summary combining transcript, slides, and related documents.
TD Cowen 46th Annual Health Care Conference summary
2 Mar, 2026Strategic initiatives and organizational changes
Implemented a new launch team structure, reallocating tenured staff and establishing regional leadership to improve system launches and utilization efficiency.
Launch team model aims to halve the time from purchase order to first 10 cases, with a goal for over half of new systems in 2024 to launch under this model.
Commercial restructuring separates launch and utilization teams, focusing the latter solely on same-store sales growth.
Incentive plans simplified to reward productivity, not behaviors, driving higher accountability and performance.
Organizational changes rolled out in January, with strong internal enthusiasm and stable attrition rates.
Inventory management and sales dynamics
Achieved near 1-to-1 handpiece inventory to procedure volume ratio, eliminating prior overstocking driven by end-of-quarter incentives.
Inventory equilibrium reached, with ongoing monitoring and adjustments as 200+ new systems are placed in 2024.
Discontinued volume-based discounts, returning customers to contracted prices without renegotiation.
Inventory levels now reflect natural usage patterns, supporting guidance and reducing revenue downside risk.
Capital strategy and forward-looking guidance
System placements for 2026 modeled to remain flat versus 2025, with pricing stable or slightly up.
Initiating a replacement strategy for legacy systems, offering trade-in credits to upgrade to HYDROS, with a larger focus expected in 2027–2028.
Exploring operational leases to expand access, with pilots planned for 2024 and broader rollout in future years.
2026 is positioned as a build year to develop capabilities for future replacement and leasing strategies.
Latest events from PROCEPT BioRobotics
- Q2 revenue up 61% year-over-year, gross margin at 59%, and cash reserves strong at $214.1M.PRCT
Q2 20248 Jul 2026 - Aquablation's clinical success and broad coverage drive rapid adoption and expansion in urology.PRCT
45th Annual William Blair Growth Stock Conference8 Jul 2026 - Q3 2024 revenue up 66% with record gross margin and HYDROS launch driving strong growth.PRCT
Q3 20248 Jul 2026 - Aquablation is poised for leadership in BPH and prostate cancer, with accelerating growth and margin expansion.PRCT
Conference presentation2 Jul 2026 - Operational realignment and clinical innovation drive growth and profitability in BPH and prostate cancer.PRCT
46th Annual William Blair Growth Stock Conference2 Jun 2026 - Revenue, margin, and growth initiatives exceeded targets; new strategies and trials drive future upside.PRCT
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue up 20% to $83.1M, gross margin 65%, net loss widens, guidance strong.PRCT
Q1 20261 May 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance focus.PRCT
Proxy filing23 Apr 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay on June 9, 2026.PRCT
Proxy filing23 Apr 2026